Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BPH GlobalASX:BP8DF -50.00% Intrinsic Value: Projected FCF is A$-0.02 as of Sep. 16, 2026. The stock has 6 warning signs investors should review. Among 635 Drug Manufacturers companies, BPH Global ranks worse than 157480.16% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-09-16), BPH Global's Intrinsic Value: Projected FCF is A$-0.02. The stock price of BPH Global is A$0.01. Therefore, BPH Global's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.
The historical rank and industry rank for BPH Global's Intrinsic Value: Projected FCF or its related term are showing as below:
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of BPH Global was 0.56. The lowest was 0.25. And the median was 0.41.
ASX:BP8DF's Price-to-Projected-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.5 * Ranked among companies with meaningful Price-to-Projected-FCF only.
BPH Global (ASX:BP8DF) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
BPH Global's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
0.01
/
-0.45404151582622
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BPH Global Intrinsic Value: Projected FCF Related Terms
BPH Global Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for BPH Global's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:BP8DF vs ZTS, UTHR: Intrinsic Value: Projected FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BPH Global's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BPH Global Price-to-Projected-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BPH Global's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where BPH Global's Price-to-Projected-FCF falls into.
BPH Global Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of A$-0.02 mean?
BPH Global (ASX:BP8DF) has a Intrinsic Value: Projected FCF of A$-0.02 as of Sep. 16, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on BPH Global and its competitors. According to the industry distribution chart, BPH Global ranks #999999 out of 635 companies in the Drug Manufacturers industry.
Is BPH Global's Intrinsic Value: Projected FCF too high?
BPH Global's current Intrinsic Value: Projected FCF is A$-0.02. Based on the distribution chart, BPH Global ranks #999999 out of 635 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does BPH Global's Intrinsic Value: Projected FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, BPH Global ranks #999999 out of 635 companies for Intrinsic Value: Projected FCF. This places BPH Global in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Drug Manufacturers company?
The median Intrinsic Value: Projected FCF among Drug Manufacturers companies is 1.50, based on 635 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on BPH Global and its competitors. For the Drug Manufacturers industry, the median Intrinsic Value: Projected FCF is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BPH Global's current Intrinsic Value: Projected FCF is A$-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BPH Global stock overvalued right now?
BPH Global (ASX:BP8DF) has a current Intrinsic Value: Projected FCF of A$-0.02. The current Intrinsic Value: Projected FCF is A$-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For BPH Global (ASX:BP8DF), the current Intrinsic Value: Projected FCF is A$-0.02 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BPH Global Ltd is a plant-focused biotechnology company with a focus on producing foods, health, and cosmetic products that deliver Traditional Chinese Medicine (TCM)-based health outcomes. It focuses on the research, development, production, and commercialization of TCM products, including bird's nest, seaweeds, and sea plants, which serve as sustainable plant-based protein sources and ingredients for food, nutrition, healthcare, cosmetics, and personal care industries. The company's geographical segment includes Australia, Indonesia, and China. The company's products comprise raw and processed bird's nest, sea grapes (Caulerpa lentillifera), and other seaweeds and sea plants.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BP8DF has been successfully added to your 
